西南医科大学学报2024，Vol.47Issue(2)：117-122,135,7.DOI:10.3969/j.issn.2096-3351.2024.02.005
前列腺癌靶向放射性核素显像剂的研究进展
Research progress of targeted radionuclide imaging agents for prostate cancer
摘要
Abstract
In recent years,the incidence of prostate cancer(PCa)has gradually increased,positron emission tomography(PET)and single pho-ton emission computed tomography(SPECT)technology have been rapidly popularized,the research and development of radiopharmaceuticals for PCa diagnosis has been developed rapidly.The development of novel radiopharmaceuticals for diagnosing prostate cancer(PCa)primarily focuses on target-ing prostate-specific membrane antigens(PSMA)through drug labeling,including specific antibodies and small molecule inhibitors.At the same time,other targets related to prostate cancer have been actively explored,and good progress has been made in clinical practice.This article reviewed the recent development of radiopharmaceuticals for the diagnosis of specific molecular targets of prostate cancer.关键词
前列腺癌/正电子发射断层显像/单光子发射计算机断层显像/前列腺特异性膜抗原Key words
Prostate cancer/PET/SPECT/PSMA分类
医药卫生引用本文复制引用
谢强..前列腺癌靶向放射性核素显像剂的研究进展[J].西南医科大学学报,2024,47(2):117-122,135,7.基金项目
安徽省重点研究与开发计划项目(2022e07020004) （2022e07020004）
